Accessibility Menu

Emergent BioSolutions(FRA) ER4

Market Cap€258.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€5.19
+2.88%
+0.15Today

Emergent BioSolutions Financials at a Glance

Market Cap

€258.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€660.45

Net Income (TTM)

-€152.27

EPS (TTM)

-€3.06

P/E Ratio

-1.65

Dividend

€0.00

Beta (Volatility)

0.26 (Low)

Price

€5.19

Volume

0

Open

€5.05

Previous Close

€5.19

Daily Range

€5.05 - €5.19

52-Week Range

€3.81 - €11.72

Estimated Earnings Date

N/A

ER4 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Emergent BioSolutions

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Industry

Biotechnology

Sector

Health Care

Employees

900

CEO

Joseph C. Papa, MBA

Website

www.emergentbiosolutions.com

ER4 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-40.31%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-60.61%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€258.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

51.27M

Volume

0

Avg. Volume

113.712

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Emergent BioSolutions Performance Analysis

Emergent BioSolutions annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 1,063,299,057-29.1%
20232023-12-31EUR 970,571,507-8.7%
20242024-12-31EUR 964,785,909-0.6%
20252025-12-31EUR 658,262,019-31.8%
Emergent BioSolutions annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -4.02N/A
20232023-12-31EUR -13.74241.9%
20242024-12-31EUR -3.32-75.8%
20252025-12-31EUR 0.82N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€201.51

+1.6%

Gross Profit

€103.21

+2.0%

Gross Margin

51.22%

+1.3%

Market Cap

€258.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€0.42

N/A

Employees

900

N/A

Net Income

-€154.98

+14.6%

EBITDA

€78.01

+3.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€637.72

-21.0%

Total Debt

€514.48

+0.9%

Accounts Receivable

€166.19

+2.4%

Inventory

€265.55

+0.9%

Long Term Debt

€513.16

+0.9%

Short Term Debt

€1.31

+0.9%

Return on Assets

-13.94%

-1.4%

Return on Invested Capital

-16.76%

+1.1%

Free Cash Flow

€46.25

+0.5%

Operating Cash Flow

€48.07

+0.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About ER4

What is the current price of Emergent BioSolutions?

Emergent BioSolutions is trading at €5.19 per share.

What is the 52-week range for Emergent BioSolutions?

Over the past 52 weeks, Emergent BioSolutions has traded between €3.81 and €11.72.

How much debt does Emergent BioSolutions have?

As of the most recent reporting period, Emergent BioSolutions reported total debt of €514.48M.

How much cash does Emergent BioSolutions have on hand?

Emergent BioSolutions reported €123.24M in cash and cash equivalents in its most recent financial results.

What is Emergent BioSolutions’s dividend yield?

Emergent BioSolutions does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services